Top Markets
#1 COTI COTI +40.13%
#2 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +32.72%
#3 Bitcoin Cash Bitcoin Cash +31.68%
#4 Fabric Protocol Fabric Protocol +31.09%
#5 GALA GALA +28.74%
#6 Tutorial Tutorial +27.35%
#7 Talus Network Talus Network +26.03%
#8 Magma Finance Magma Finance +24.61%
#9 Zora Zora +23.81%
#10 Arowana Arowana +22.89%
Coin of the day
COTI COTI
設定
言語
日本
通貨
USD
テーマ
Lytix Biopharma AS Lytix Biopharma AS

Lytix Biopharma AS

LYTIX
株式のランク #24450
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology... Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.
株価
$0.78611575
時価総額
$60.45M
変化（1日）
0.00%
変化（1年）
-12.06%
国
NO
取引 Lytix Biopharma AS (LYTIX)

カテゴリー

Healthcare
Lytix Biopharma AS（LYTIX）のP/S比率
2026 時点のP/S比率 TTM: 0
Lytix Biopharma AS の最新の財務報告および株価によると、現在のP/S比率（TTM）は 0 です。2026 年末時点でのP/S比率は 0 でした。
Lytix Biopharma AS の P/S 比率の履歴（2026 ～ 2026）
各年末時点のP/S比率
年 P/S比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/S比率
企業 P/S比率 P/S比率の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH